Quick Facts
| Property | Value |
|---|---|
| Category | Melanocortin Receptor Agonist |
| Risk Level | High |
| Research Status | Strong Human Evidence |
| Administration | Subcutaneous Injection |
| Typical Frequency | PRN / 1–2 Times Weekly |
| Estimated Half-Life | Approximately 2–6 Hours |
| Primary Research Interest | Libido / Sexual Function / Arousal Signaling |
This material is provided strictly for educational and informational purposes related to peptide research and melanocortin receptor agonists. PT-141 (Bremelanotide) is a biologically active compound capable of altering central nervous system arousal pathways, sexual desire signaling, and melanocortin receptor activity. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Summary
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist originally developed from Melanotan research and subsequently investigated for its effects on sexual desire, arousal, and sexual function.
Unlike traditional erectile dysfunction medications that primarily influence blood flow, PT-141 acts centrally through the nervous system by stimulating melanocortin receptors involved in sexual arousal and desire signaling.
What People Commonly Claim
- Increased libido
- Improved erectile function
- Enhanced sexual desire
- Increased arousal
- Improved sexual performance
What the Literature Actually Shows
- PT-141 increases sexual desire in appropriately selected populations.
- PT-141 acts through central nervous system pathways rather than vascular mechanisms.
- Clinical trials demonstrate efficacy in hypoactive sexual desire disorder (HSDD).
- Nausea is the most common adverse effect.
- Transient blood-pressure elevations can occur.
- Human efficacy data are substantially stronger than those available for most research peptides.
CKF Transparency Note: Unlike many compounds discussed within peptide communities, PT-141 has undergone extensive human clinical testing and ultimately received FDA approval as Bremelanotide for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. The quality of evidence supporting biological activity is considerably stronger than that available for most experimental peptides.
2. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 0.5 mg = 0.100 mL (10 units)
• 1.5 mg = 0.300 mL (30 units)
• 2.0 mg = 0.400 mL (40 units)
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: 0.5–1.5 mg
- Maximum Single Dose: 2 mg
- Frequency: 1–2 times weekly as needed (PRN)
- Monthly Limit: Do not exceed 8 administrations per month
- Cycle Length: PRN use rather than continuous cycling
- Special Notes: PT-141 is commonly administered several hours prior to anticipated sexual activity. Many users report that effects develop gradually rather than immediately. Some researchers and users incorporate periodic breaks after extended use in an attempt to reduce theoretical receptor-desensitization concerns, although formal evidence for optimal cycling strategies remains limited.
CKF Evidence Note: Clinical literature supports intermittent administration rather than frequent daily use. The strongest evidence base involves PRN administration for sexual-desire enhancement rather than chronic continuous dosing.
4. Mechanism of Action
PT-141 functions as a melanocortin receptor agonist, primarily influencing central nervous system pathways involved in sexual desire and arousal.
- Melanocortin receptor activation
- Central nervous system arousal signaling
- Libido modulation
- Sexual-desire pathway activation
- Neurological stimulation of sexual response systems
- Potential enhancement of erectile-response signaling
Unlike phosphodiesterase-5 inhibitors such as sildenafil or tadalafil, PT-141 does not primarily function through vasodilation. Instead, it operates through neural pathways associated with sexual motivation and arousal.
5. Potential Benefits
- Potential enhancement of sexual desire
- Improved arousal signaling
- Potential improvement in libido
- Possible support for erectile function
- Potential enhancement of sexual satisfaction
- May complement traditional erectile dysfunction therapies
6. Potential Risks / Side Effects
High
- Nausea
- Flushing
- Headaches
- Transient blood-pressure elevation
- Fatigue
- Dizziness
- Injection-site reactions
- Potential receptor-desensitization concerns with overuse
Nausea represents the most consistently reported adverse effect in clinical studies. Blood-pressure elevations are generally transient but remain clinically relevant, particularly for individuals with cardiovascular risk factors.
7. Half-Life
PT-141 is commonly reported as possessing an elimination half-life of approximately 2–6 hours.
Despite this relatively short pharmacokinetic profile, effects on libido and sexual arousal may persist significantly longer than measurable plasma concentrations.
This prolonged subjective effect is believed to result from downstream neurological signaling initiated through melanocortin receptor activation.
8. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
9. Contraindications / Warnings
- Uncontrolled hypertension
- Severe cardiovascular disease
- Pregnancy or breastfeeding
- Use alongside stimulant compounds
- Known hypersensitivity to formulation ingredients
10. Further Study
Tier 1 — Essential Reading
- Novel Emerging Therapies for Erectile Dysfunction
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder
- Melanocortin Receptors, Melanotropic Peptides and Penile Erection
Tier 2 — Advanced Reading
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Current Evidence Gaps
- Long-term use beyond approved treatment populations
- Male-specific outcome studies
- Optimal combination strategies with PDE5 inhibitors
- Receptor-desensitization characterization
- Comparative effectiveness studies
11. Research References
- PubMed
- PubMed Central (PMC)
- Melanocortin receptor research
- Sexual medicine literature
- Clinical endocrinology research
- FDA-reviewed clinical trial data
12. Last Reviewed
June 2026
PT41: #56-30-150